Immune Design (IMDZ): TheraVectys Settlement Removes A Small Overhang - Jefferies

October 24, 2016 8:09 AM EDT
Get Alerts IMDZ Hot Sheet
Price: $5.40 -0.92%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 22 | Down: 17 | New: 13
Trade IMDZ Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Immune Design (NASDAQ: IMDZ) after announcing a settlement with TheraVectys SA.

The company announced settlement of the ongoing IP dispute with TheraVectys for a modest sum (up to $7.25M). Though this was not likely a major overhang for investors, the analyst believes elimination of the lingering issue should enable IMDZ to increase its share price upside if the cancer pipeline readouts are positive.

No change to the price target of $17.

For an analyst ratings summary and ratings history on Immune Design click here. For more ratings news on Immune Design click here.

Shares of Immune Design closed at $6.95 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment